Meny
Meny
Cellcolabs Clinical is conducting clinical trials in the Bahamas using Mesenchymal Stem Cells (MSCs). Our MSCs are produced in Sweden and based on a manufacturing protocol developed at the world-renowned Karolinska Institute.
Mesenchymal stem cells (MSCs) are a type of multipotent stem cell with anti-inflammatory, immunomodulatory and regenerative characteristics. They have been intensively researched over the past decades, and currently, there are hundreds of clinical trials with MSCs for a broad spectrum of conditions (1).
The MSCs used in these trials are produced by Cellcolabs AB at their facility in Stockholm, Sweden. The production process has been optimised through 25 years of academic research, and the cells are quality controlled according to the guidelines of the International Society for Cell and Gene Therapy (2). The manufacturing is approved by the Swedish Medical Products Agency and certified under GMP (Good Manufacturing Practice) standards. The clinical trials have received approval by local authorities.
Cellcolabs’ MSCs are derived from the bone marrow of healthy donors aged 18-30. These cells are likely more potent than cells derived from trial participants themselves (3-4). Using donated cells also means that trial participants do not need to endure cell extraction as part of the trial.
We are currently conducting several clinical trials with MSCs. These include Prevention of cardiovascular disease, Musculoskeletal injuries and/or degeneration; and Ageing frailty.
Eligibility for the trials will be determined by the relevant Principal Investigator. More information on inclusion and exclusion criteria is available during the sign-up process.
This clinical trial investigates the potential of MSCs in prevention of cardiovascular disease and follows several longevity and disease biomarkers. Cardiovascular disease is the leading cause of death globally, taking an estimated 20 million lives each year. Prevention is a proactive approach to healthcare that seeks to maintain health and prevent development of illness.
You may be eligible if you:
Musculoskeletal injuries and degeneration may occur for various reasons, such as accidents, sports injuries, genetics, or just wear and tear. Depending on your condition you may be eligible for local and/or systemic treatment.
You may be eligible if you are 18 years or older and have:
The geriatric syndrome of frailty is a common clinical syndrome based on the accumulation of multi-systemic function declines and the increase in susceptibility to stressors during biological ageing. This can manifest in a variety of symptoms, such as decreased muscle strength, reduced mobility, and impaired cognitive function. Frailty can also increase an elderly persons risk of falls, hospitalization, and other negative health outcomes.
You may be eligible if you:
Osteoarthritis is the most common form of arthritis and is also known as degenerative arthritis and OA. It occurs most frequently in the hands, hips, and knees. A common symptom of OA is a stiff and painful feeling around the joints.
Please note that this is not a separate trial. Treatments for OA will be included in the musculoskeletal injuries and degeneration trial.
This clinical trial investigates the potential of MSCs in prevention of cardiovascular disease and follows several longevity and disease biomarkers. Cardiovascular disease is the leading cause of death globally, taking an estimated 20 million lives each year. Prevention is a proactive approach to healthcare that seeks to maintain health and prevent development of illness. You may be eligible if you:
Musculoskeletal injuries and degeneration may occur for various reasons, such as accidents, sports injuries, genetics, or just wear and tear. Depending on your condition you may be eligible for local and/or systemic treatment. You may be eligible if you are 18 years or older and have:
The geriatric syndrome of frailty is a common clinical syndrome based on the accumulation of multi-systemic function declines and the increase in susceptibility to stressors during biological ageing. This can manifest in a variety of symptoms, such as decreased muscle strength, reduced mobility, and impaired cognitive function. Frailty can also increase an elderly persons risk of falls, hospitalization, and other negative health outcomes. You may be eligible if you:
Osteoarthritis is the most common form of arthritis and is also known as degenerative arthritis and OA. It occurs most frequently in the hands, hips, and knees. A common symptom of OA is a stiff and painful feeling around the joints. Please note that this is not a separate trial. Treatments for OA will be included in the musculoskeletal injuries and degeneration trial.
Our clinical trials are conducted in the Bahamas, a country known for its high-quality healthcare and ambitious research in regenerative medicine.
The Bahamas is a destination for both tourism and medicine, and the country is at the forefront of clinical stem cell applications. They allow patient-funded clinical trials, which is an opportunity to accelerate the research.
Our local partnering physicians have long experience of stem cell therapies. The clinical trials are approved by the Bahamas National Stem Cell Ethics Committee.
2. Dominici M, Le Blanc K, Mueller I, et al. Minimal criteria for defining multipotent mesenchymal stromal cells. The International Society for Cellular Therapy position statement. Cytotherapy. 2006;8(4):315-317. doi:10.1080/14653240600855905
3. Schultz, M.B. and Sinclair, D.A., 2016. When stem cells grow old: phenotypes and mechanisms of stem cell aging. Development, 143(1), pp.3-14.
4. Karin Stenderup, Jeannette Justesen, Christian Clausen, Moustapha Kassem, Aging is associated with decreased maximal life span and accelerated senescence of bone marrow stromal cells, Bone, Volume 33, Issue 6, 2003, Pages 919-926, ISSN 8756-3282, https://doi.org/10.1016/j.bone.2003.07.005.